| # | Title | Journal | Year | Citations |
|---|
| 1 | Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer | New England Journal of Medicine | 2005 | 4,601 |
| 2 | Nivolumab plus Ipilimumab in Advanced Melanoma | New England Journal of Medicine | 2013 | 3,776 |
| 3 | Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial | Lancet, The | 2010 | 2,857 |
| 4 | American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer | Journal of Clinical Oncology | 2010 | 2,667 |
| 5 | ESMO consensus guidelines for the management of patients with metastatic colorectal cancer | Annals of Oncology | 2016 | 2,545 |
| 6 | Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer | New England Journal of Medicine | 2013 | 1,971 |
| 7 | Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers | JAMA - Journal of the American Medical Association | 2017 | 1,898 |
| 8 | Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | New England Journal of Medicine | 2018 | 1,854 |
| 9 | Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial | Lancet, The | 2012 | 1,752 |
| 10 | Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma | New England Journal of Medicine | 2017 | 1,752 |
| 11 | Renal cell carcinoma | Nature Reviews Disease Primers | 2017 | 1,727 |
| 12 | Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer | New England Journal of Medicine | 2015 | 1,526 |
| 13 | International evaluation of an AI system for breast cancer screening | Nature | 2020 | 1,458 |
| 14 | Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial | Lancet Oncology, The | 2017 | 1,376 |
| 15 | Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater | Journal of Clinical Oncology | 2019 | 1,144 |
| 16 | Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study | Lancet Oncology, The | 2015 | 1,100 |
| 17 | Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial | Lancet Oncology, The | 2018 | 1,089 |
| 18 | Rethinking ovarian cancer: recommendations for improving outcomes | Nature Reviews Cancer | 2011 | 1,084 |
| 19 | Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002) | Gut | 2010 | 1,000 |
| 20 | EFSUMB Guidelines and Recommendations on the Clinical Use of Ultrasound Elastography. Part 1: Basic Principles and Technology | Ultraschall in Der Medizin | 2013 | 961 |
| 21 | Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update | Archives of Pathology and Laboratory Medicine | 2014 | 961 |
| 22 | Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial | Lancet Oncology, The | 2016 | 941 |
| 23 | Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma | Journal of Clinical Oncology | 2017 | 930 |
| 24 | Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS) | Lancet, The | 2005 | 927 |
| 25 | Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial | Lancet, The | 2016 | 878 |
| 26 | Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial | Lancet Oncology, The | 2016 | 832 |
| 27 | Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven | Journal of Clinical Oncology | 2008 | 819 |
| 28 | Magnetic resonance imaging of the breast: Recommendations from the EUSOMA working group | European Journal of Cancer | 2010 | 813 |
| 29 | Prostate cancer | Lancet, The | 2016 | 801 |
| 30 | Multiple newly identified loci associated with prostate cancer susceptibility | Nature Genetics | 2008 | 796 |
| 31 | Oesophageal cancer | Lancet, The | 2017 | 796 |
| 32 | WFUMB Guidelines and Recommendations for Clinical Use of Ultrasound Elastography: Part 1: Basic Principles and Terminology | Ultrasound in Medicine and Biology | 2015 | 718 |
| 33 | Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? | European Journal of Cancer | 1998 | 700 |
| 34 | EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Long Version) | Ultraschall in Der Medizin | 2017 | 659 |
| 35 | Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial | Nature Medicine | 2018 | 649 |
| 36 | Magnetic Resonance Imaging for the Detection, Localisation, and Characterisation of Prostate Cancer: Recommendations from a European Consensus Meeting | European Urology | 2011 | 642 |
| 37 | Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial | Lancet Oncology, The | 2013 | 631 |
| 38 | WFUMB Guidelines and Recommendations for Clinical Use of Ultrasound Elastography: Part 3: Liver | Ultrasound in Medicine and Biology | 2015 | 620 |
| 39 | Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study | Lancet Oncology, The | 2011 | 612 |
| 40 | Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study | Lancet Oncology, The | 2019 | 611 |
| 41 | Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal | Cell | 2018 | 609 |
| 42 | Prognostic Value of Ki67 Expression After Short-Term Presurgical Endocrine Therapy for Primary Breast Cancer | Journal of the National Cancer Institute | 2007 | 608 |
| 43 | Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial | Lancet, The | 2020 | 603 |
| 44 | Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2019 | 592 |
| 45 | Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression | Oral Oncology | 2018 | 589 |
| 46 | High intensity focused ultrasound: Physical principles and devices | International Journal of Hyperthermia | 2007 | 579 |
| 47 | The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 | JAMA Oncology | 2020 | 572 |
| 48 | International consensus statement on the peri‐operative management of anaemia and iron deficiency | Anaesthesia | 2017 | 571 |
| 49 | Guidelines for the management of oesophageal and gastric cancer | Gut | 2011 | 570 |
| 50 | Outcome Prediction for Estrogen Receptor-Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics | Journal of the National Cancer Institute | 2008 | 566 |
